Evidence map›Paper›PMID 30412655›Full record

Trial reportJournal of diabetes investigation2019

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME

Takashi Kadowaki, Masaomi Nangaku, Stefan Hantel, Tomoo Okamura, Maximilian von Eynatten, Christoph Wanner, Audrey Koitka-Weber

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06890143 (The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children), which is not on this map. Cited by 42 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 6 pooled it
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06890143 phase3recruitingnot on this mapstarted 2025, after this paper: background citation

The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children: a Prospective, Randomized Crossover Trial

TypeinterventionalSponsorChildren's Hospital of Fudan UniversityRan2025 to 2027Enrolled44ConditionsPediatric Hereditary Kidney DiseasesArmsDapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks, Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 6 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Takashi KadowakiGraduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Masaomi NangakuGraduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Stefan HantelBoehringer Ingelheim International GmbH, Biberach, Germany.
Tomoo OkamuraNippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan.
Maximilian von EynattenBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Christoph WannerDepartment of Medicine, Würzburg University Clinic, Würzburg, Germany.
Audrey Koitka-WeberBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Boehringer Ingelheim (Germany) · DEThe University of Tokyo · JPUniversitätsklinikum Würzburg · DEBoehringer Ingelheim (Japan) · JP

Funding

Boehringer IngelheimEli Lilly and Company Diabetes Alliance
6 · The paper itself

Abstract

AIMS/

introductionIn the EMPA-REG OUTCOME MATERIALS AND

methodsParticipants in the EMPA-REG OUTCOME

resultsOf 7,020 treated patients, 1,517 (26.1%) were Asian. In this subgroup, consistent with the overall trial population, empagliflozin reduced the risk of incident or worsening nephropathy (hazard ratio 0.64, 95% confidence interval 0.49-0.83), progression to macroalbuminuria (hazard ratio 0.64, 95% confidence interval 0.49-0.85) and the composite of doubling of serum creatinine, initiation of renal-replacement therapy or renal death (hazard ratio 0.48, 95% confidence interval 0.25-0.92). Furthermore, empagliflozin-treated participants showed slower eGFR decline versus placebo, and showed rapid urine albumin-to-creatinine ratio reduction at week 12, maintained through week 164, with effects most pronounced in those with baseline microalbuminuria or macroalbuminuria. The kidney safety profile of empagliflozin in the Asian subgroup was similar to the overall trial population.

conclusionsIn Asian patients from the EMPA-REG OUTCOME

Indexed as

AlbuminuriaAsian PeopleBenzhydryl CompoundsBiomarkersBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic NephropathiesFollow-Up StudiesGlomerular Filtration RateGlucosidesGlycated HemoglobinHumansPrognosisRenal Insufficiency, ChronicRisk FactorsBenzhydryl CompoundsBiomarkersBlood GlucoseempagliflozinGlucosidesGlycated Hemoglobinhemoglobin A1c protein, humanSodium-Glucose Transporter 2 InhibitorsDiabetic kidney diseaseEmpagliflozinType 2 diabetes mellitus

Identifiers

PMID30412655
PMCPMC6497612
OpenAlexW2900442056

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.